Background: Ceruloplasmin is an acute phase protein with plasma copper binding properties, and\nis a potent extracellular antioxidative enzyme. Inflammation and oxidative stress might explain\nthe role of ceruloplasmin in the pathophysiology of heart failure. Study objective: The objective is\nto assess the correlation of ceruloplasmin levels with biomarkers of cardiac remodelling and myofibrosis\nin patients with acute decompensated heart failure. Patients and methods: Blood samples\nwere taken and serum levels of soluble ST2, galectin-3, NT-proBNP and ceruloplasmin were analysed\nin 31 consecutive patients with systolic HF referred to tertiary care nurse lead heart failure\nclinic with acute decompensated CHF requiring i.v. diuretics. The mean patients� age was 68 years,\nmean left ventricular ejection fraction (LV EF) was 29%, 66% patients had ischemic aetilogy of\nCHF and 33% had atrial fibrillation. Results: The mean ceruloplasmin level was 0.243 g/l, mean\ngalectin-3 level was 1.26 ng/ml, mean sST2 level was 38.15 ng/ml, and mean NT-proBNP was 1927\npg/ml. The ceruloplasmin level correlated with NT-proBNP (r = 0.58, p < 0.05) and with sST2 (r =\n0.77, p < 0.001), sST2 levels correlated significantly with NT-proBNP (r = 0.66, p < 0.01). The ceruloplasmin\nlevel did not correlate with galectin-3 concentration. Conclusion: The ceruloplasmin\nlevel correlates with the biomarkers of cardiac remodelling (NT-proBNP, sST2), but not with the\nbiomarker of myofibrosis (galectin-3). This finding supports the hypothesis of inflammatory re-sponse in acute decompensated heart failure.
Loading....